PodParley PodParley
PodParley
MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled episode artwork

EPISODE · Jan 15, 2021 · 9 MIN

MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled

from MPR Weekly Dose

This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; and the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.

Episode metadata supplied by the publisher feed · Published Jan 15, 2021

Embed this episode

Ready to play

MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled

0:00 9:44

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 9 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on January 15, 2021.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!